Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. [electronic resource]
Producer: 20190730Description: 819-820 p. digitalISSN:- 1526-632X
No physical items for this record
Publication Type: Editorial; Comment
There are no comments on this title.
Log in to your account to post a comment.